- In August 2021, in an agreement signed between Yuyu Pharma and Novartis Korea, Yuyu obtained the exclusive distribution rights for three prescription drugs, including Tegretol, a medication containing the drug carbamazepine used to treat diseases including epilepsy
- In February 2021, A leading provider of remote diagnostics and monitoring, BioTelemetry, Inc., was purchased by Koninklijke Philips N.V.
Frequently Asked Questions
The market is segmented based on Segmentation, By Condition (Epilepsy Drug Resistant/Intractable Epilepsy, Others), Drug (First-Generation, Second-Generation, Third-Generation), Distribution Channel (Hospitals, Clinics, Retail Pharmacies, Online Pharmacies), End Users (Hospitals, Clinics, Ambulatory Surgical Centers, Diagnostic Centers) – Industry Trends and Forecast to 2031
.
The Global Epilepsy Treatment Market size was valued at USD 6.50 USD Million in 2023.
The Global Epilepsy Treatment Market is projected to grow at a CAGR of 6.2% during the forecast period of 2024 to 2031.
The major players operating in the market include Pfizer , Novartis AG, Abbott, Neurelis , GSK plc, Johnson & Johnson Services , Teva Pharmaceutical Industries , Sumitomo Dainippon Pharma Co. Ltd, Bausch Health Companies , Sanofi, Takeda Pharmaceutical Company Limited, UCB S.A., Marinus Pharmaceuticals , Eisai Co. Ltd, H. Lundbeck A/S, Supernus Pharmaceuticals , DAIICHI SANKYO COMPANY LIMITED.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
